68-GaNOTA-Anti-HER2 VHH1
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 68-GaNOTA-Anti-HER2 VHH1, covering 2024-02-16 to 2024-02-16. Get the full timeline:
Most recent: Clinical Trial Update: Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients [Phase 2]